The 4th ISCC
December 2, 1999
Nagai Memorial Hall
Program
09:00-09:05
Haruo Sugano (Cancer Chemotherapy Center, Japan)
Welcome and Introduction
I New Strategies for Anticancer Drug Screening
Chairperson: Takashi Tsuruo (University of Tokyo, Japan)
09:05-09:30
John R. Lamb (Fred Hutchinson Cancer Research Center, USA)
HSP90 inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons
09:30-09:55
John N. Weinstein (National Cancer Institute, USA)
Gene expression profiling for cancer chemotherapy: Genomics and bioinformatics
09:55-10:05
Discussion
10:05-10:25
Coffee Break
II Drug Development Targeted at Altered Gene Function in Tumors
Chairpersons:Jean-Pierre Armand (Institut Gustave Roussy,
France)
Ryuzo Ueda (Nagoya City Univ. Med. School, Japan)
10:25-10:45
Hirofumi Arakawa (University of Tokyo, Japan)
Identification of target genes for p53, their roles in p53 tumor suppression, and their application for cancer therapy
10:45-11:10
Elisabeth Buchdunger (Novartis Pharma AG, Switzerland)
Inhibition of Abl and PDGF-R protein tyrosine kinases
11:10-11:25
Shin-ichi Nihira (Nippon Roche K.K., Japan)
Development of HER2 specific humanized antibody (Trastuzumab) for the treatment of metastatic breast cancer
11:25-11:50
Randall K. Johnson (SmithKline Beecham Pharmaceuticals, USA)
Inhibition of cell cycle regulation at G2/M phase
11:50-12:00
Discussion
12:00-12:50
Lunch Break
III New Molecular Targets for Anticancer Drug Development
Chairpersons:Susan Arbuck (National Cancer Institute, USA)
Noboru
Horikoshi (Cancer Chemotherapy Center, Japan)
12:50-13:15
Julian Adams (LeukoSite, Inc., USA)
Proteasome inhibitors: potent and effective anti-tumor agents
13:15-13:30
Tamio Mizukami (Kyowa Hakko Kogyo Co., Ltd., Japan)
Identification of a novel proteasome inhibitor, UCK14A, by microbial screening using yeast-based assay
13:30-13:45
Kazuyuki Itoh (Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan)
Anti-invasive effects of Rho-kinase (ROCK) inhibitor Y-27632
13:45-14:00
Hidenori Nakajima (Fujisawa Pharmaceutical Co., Ltd., Japan)
FK228, a novel histone deacetylase inhibitor
14:00-14:15
Osamu Nakanishi (Mitsui Pharmaceuticals, Inc., Japan)
A novel synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors
14:15-14:40
Igor B. Roninson (University of Illinois, USA)
Induction of tumor cell senescence by anticancer agents
14:40-14:50
Discussion
14:50-15:10
Coffee Break
IV New Interesting Drugs under Clinical Consideration
Chairpersons:Herbert M. Pinedo (Free University, Netherlands)
Masahiro
Fukuoka (Kinki Univ. School of Med., Japan)
15:10-15:40
Jean-Pierre Armand (Institut Gustave Roussy, France)
New anticancer drug in phase I in France
15:40-16:10
Edward A. Sausville (Natonal Cancer Institute, USA)
Flavopiridol and other new anticancer drugs in Phase I/II at the NCI
16:10-16:20
Discussion
V Clinical Evaluation of Non-cytotoxic Agents for Cancer
Chairpersons:Edward A. Sausville (National Cancer Institute,
USA)
Yutaka Ariyoshi (Aichi Hospital, Japan)
16:20-16:40
Nagahiro Saijo (National Cancer Center Hospital, Japan)
Could it be possible to obtain licenses of non cytotoxic target-based drugs?
16:40-17:00
Elizabeth A. Eisenhauer (Queen’s University, Canada)
Measure for measure
17:00-17:20
Jaap Verweij (Rotterdam Cancer Institute, Netherlands)
Trial design for new cytostatic agents: Art or artificial?
17:20-17:40
Susan Arbuck (National Cancer Institute, USA)
Molecular targets in early clinical trials
17:40-17:55
Discussion
17:55-18:00
Takashi Tsuruo (Univ. Tokyo, Japan)
Closing Remark
18:00-19:00
Mixer
